Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-MIBG or Lorlatinib Added to Intensive Therapy for High-Risk Neuroblastoma
NCT03126916Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- May 2018
- Primary completion
- Sep 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of Iobenguane I-131, lorlatinib in neuroblastoma, ganglioneuroblastoma (GNB), sponsored by Children's Oncology Group. Started May 2018; status: recruiting.
02
Drugs
Iobenguane I-131lorlatinib
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT03126916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126916.